Referenser

  1. Johnell O, Gullberg B, Allander E, Kanis JA. The apparent incidence of hip fracture in Europe: a study of national register sources. Osteoporos Int. 1992;2:298-302.
  2. Eklund F, Nordstrom A, Neovius M, Svensson O, Nordstrom P. Variation in fracture rates by country may not be explained by differences in bone mass. Calcif Tissue Int. 2009;85(1):10-16.
  3. Michaëlsson K, Melhus H, Ferm H, Ahlbom A, Pedersen NL. Genetic liability to fractures in the elderly. Arch Intern Med. 2005;165(16):1825-1830.
  4. Riggs BL, Melton LJd. The prevention and treatment of osteoporosis N Engl J Med. 1992;327:620-627.
  5. Kharazmi M, Hallberg P, Schilcher J, Aspenberg P, Michaelsson K. Mortality After Atypical Femoral Fractures: A Cohort Study. J Bone Miner Res. 2016;31(3):491-497.
  6. Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int. 1994;4(6):368-381.
  7. Jarvinen TL, Michaelsson K, Aspenberg P, Sievanen H. Osteoporosis: the emperor has no clothes. J Intern Med. 2015;277(6):662-673.
  8. Jarvinen TL, Michaelsson K, Jokihaara J, et al. Overdiagnosis of bone fragility in the quest to prevent hip fracture. BMJ. 2015;350:h2088.
  9. Fleisch H. Development of bisphosphonates. Breast Cancer Res. 2002;4(1):30-34.
  10. Svedbom A, Hernlund E, Ivergard M, et al. Osteoporosis in the European Union: a compendium of country-specific reports. Archives of osteoporosis. 2013;8(1-2):137.
  11. Wells G, Cranney A, Peterson J, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008(1):CD004523.
  12. Wells GA, Cranney A, Peterson J, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008(1):CD001155.
  13. Wells GA, Cranney A, Peterson J, et al. Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008(1):CD003376.
  14. McClung M, Boonen S, Torring O, et al. Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J Bone Miner Res. 2011.
  15. Curtis JR, Delzell E, Chen L, et al. The relationship between bisphosphonate adherence and fracture: is it the behavior or the medication? Results from the placebo arm of the fracture intervention trial. J Bone Miner Res. 2011;26(4):683-688.
  16. Curtis JR, Westfall AO, Cheng H, Lyles K, Saag KG, Delzell E. Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res. 2008;23(9):1435-1441.
  17. Greenspan SL, Perera S, Ferchak MA, Nace DA, Resnick NM. Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: a randomized clinical trial. JAMA internal medicine. 2015;175(6):913-921.
  18. Adler RA, El-Hajj Fuleihan G, Bauer DC, et al. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016;31(1):16-35.
  19. Grey A, Bolland MJ. The effect of treatments for osteoporosis on mortality. Osteoporos Int. 2013;24(1):1-6.
  20. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357(18):1799-1809.
  21. Colon-Emeric CS, Mesenbrink P, Lyles KW, et al. Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res. 2010;25(1):91-97.
  22. Jarvinen T, Michaelsson K, Jokihaara J, et al. Authors’ reply to Lee and colleagues. BMJ. 2015;351:h3737.
  23. Bassler D, Briel M, Montori VM, et al. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA. 2010;303(12):1180-1187.
  24. Abraha I, Cherubini A, Cozzolino F, et al. Deviation from intention to treat analysis in randomised trials and treatment effect estimates: meta-epidemiological study. BMJ. 2015;350:h2445.
  25. May GS, DeMets DL, Friedman LM, Furberg C, Passamani E. The randomized clinical trial: bias in analysis. Circulation. 1981;64(4):669-673.
  26. Juni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ. 2001;323(7303):42-46.
  27. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c869.
  28. Schilcher J, Koeppen V, Aspenberg P, Michaelsson K. Risk of atypical femoral fracture during and after bisphosphonate use. N Engl J Med. 2014;371(10):974-976.
  29. Schilcher J, Koeppen V, Aspenberg P, Michaelsson K. Risk of atypical femoral fracture during and after bisphosphonate use. Acta Orthop. 2015;86(1):100-107.
  30. Ulmner M, Jarnbring F, Torring O. Osteonecrosis of the jaw in Sweden associated with the oral use of bisphosphonate. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons. 2014;72(1):76-82.
  31. Cumming RG, Nevitt MC, Cummings SR. Epidemiology of hip fractures. Epidemiol Rev. 1997;19:244-257.
  32. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17(12):1726-1733.
  33. Devold HM, Furu K, Skurtveit S, Tverdal A, Falch JA, Sogaard AJ. Influence of socioeconomic factors on the adherence of alendronate treatment in incident users in Norway. Pharmacoepidemiol Drug Saf. 2012;21(3):297-304.
  34. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81(8):1013-1022.
  35. Leavy B, Michaelsson K, Aberg AC, Melhus H, Byberg L. The Impact of Disease and Drugs on Hip Fracture Risk. Calcif Tissue Int. 2017;100(1):1-12.
  36. Byberg L, Gedeborg R, Cars T, et al. Prediction of fracture risk in men: a cohort study. J Bone Miner Res. 2012;27(4):797-807.
  37. Collins GS, Michaelsson K. Fracture risk assessment: state of the art, methodologically unsound, or poorly reported? Curr Osteoporos Rep. 2012;10(3):199-207.
  38. Jarvinen TL, Jokihaara J, Guy P, et al. Conflicts at the heart of the FRAX tool. CMAJ : Canadian Medical Association journal = journal de l’Association medicale canadienne. 2014;186(3):165-167.
  39. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19(4):385-397.
  40. Kanis JA, Oden A, Johansson H, Borgstrom F, Strom O, McCloskey E. FRAX and its applications to clinical practice. Bone. 2009;44(5):734-743.
  41. Ford N, Norris SL, Hill SR. Clarifying WHO’s position on the FRAX(R) tool for fracture prediction. Bull World Health Organ. 2016;94(12):862.
  42. Hillier TA, Cauley JA, Rizzo JH, et al. WHO absolute fracture risk models (FRAX): do clinical risk factors improve fracture prediction in older women without osteoporosis? J Bone Miner Res. 2011;26(8):1774-1782.
  43. Ensrud KE, Lui LY, Taylor BC, et al. A comparison of prediction models for fractures in older women: is more better? Arch Intern Med. 2009;169(22):2087-2094.
  44. Masud T, Binkley N, Boonen S, Hannan MT, Members FPDC. Official Positions for FRAX(R) clinical regarding falls and frailty: can falls and frailty be used in FRAX(R)? From Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(R). J Clin Densitom. 2011;14(3):194-204.
  45. Kanis J, Group obotWHOS. Assessment of osteoporosis at the primary health-care level. Sheffield, UK: World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield;2007.
  46. Järvinen TLN, Sievänen H, Khan KM, Heinonen A, Kannus P. Shifting the focus in fracture prevention from osteoporosis to falls. BMJ. 2008;336(7636):124-126.
  47. Harvey NC, Oden A, Orwoll E, et al. Falls Predict Fractures Independently of FRAX Probability: A Meta-Analysis of the Osteoporotic Fractures in Men (MrOS) Study. J Bone Miner Res. 2017.
  48. Wagner H, Melhus H, Gedeborg R, Pedersen NL, Michaelsson K. Simply ask them about their balance–future fracture risk in a nationwide cohort study of twins. Am J Epidemiol. 2009;169(2):143-149.
  49. Lang T, Cauley JA, Tylavsky F, et al. Computed tomographic measurements of thigh muscle cross-sectional area and attenuation coefficient predict hip fracture: the health, aging, and body composition study. J Bone Miner Res. 2010;25(3):513-519.
  50. Moore AZ, Caturegli G, Metter EJ, et al. Difference in muscle quality over the adult life span and biological correlates in the Baltimore Longitudinal Study of Aging. J Am Geriatr Soc. 2014;62(2):230-236.
  51. Cederholm T, Cruz-Jentoft AJ, Maggi S. Sarcopenia and fragility fractures. European journal of physical and rehabilitation medicine. 2013;49(1):111-117.
  52. Uusi-Rasi K, Patil R, Karinkanta S, et al. Exercise and vitamin D in fall prevention among older women: a randomized clinical trial. JAMA internal medicine. 2015;175(5):703-711.
  53. El-Khoury F, Cassou B, Charles MA, Dargent-Molina P. The effect of fall prevention exercise programmes on fall induced injuries in community dwelling older adults: systematic review and meta-analysis of randomised controlled trials. BMJ. 2013;347:f6234.
  54. Stattin K, Michaelsson K, Larsson SC, Wolk A, Byberg L. Leisure-Time Physical Activity and Risk of Fracture: A Cohort Study of 66,940 Men and Women. J Bone Miner Res. 2017;32(8):1599-1606.
  55. Grey A, Bolland M. Web of industry, advocacy, and academia in the management of osteoporosis. BMJ. 2015;351:h3170.
  56. Ahn R, Woodbridge A, Abraham A, et al. Financial ties of principal investigators and randomized controlled trial outcomes: cross sectional study. BMJ. 2017;356:i6770.
  57. Bero L. Industry sponsorship and research outcome: a Cochrane review. JAMA internal medicine. 2013;173(7):580-581.
  58. Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev. 2017;2:MR000033.

 

Share →